Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02639182
Other study ID # AGS-16C3F-15-3
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date May 3, 2016
Est. completion date October 2, 2020

Study information

Verified date November 2021
Source Astellas Pharma Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study was to evaluate the progression free survival (PFS), based on investigator radiologic review, of AGS-16C3F compared to axitinib in subjects with metastatic renal cell carcinoma.


Recruitment information / eligibility

Status Completed
Enrollment 133
Est. completion date October 2, 2020
Est. primary completion date October 2, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically confirmed diagnosis of RCC - Non-clear subjects must be ENPP3 positive, defined as IHC H-score =15 - Has evidence of progression on or after the last regimen received: - Clear cell subject: must have received at least 2 prior systemic regimens, one of which is an anti-VEGF agent. - Non-clear cell subject: must have received at least one prior anti-VEGF regimen - Has measurable disease according to Response Criteria for Solid Tumors (RECIST v.1.1) - Has Eastern Cooperative Group (ECOG) performance status of 0 or 1 - Has archive tumor tissue from primary tumor or metastatic site (excluding bone), for which the source and availability have been confirmed. - If no archive tissue is available, the subject may elect to have a biopsy performed to obtain tissue. - Has adequate organ function including: - Hematopoietic function as follows: 1. Absolute neutrophil count (ANC) = 1.5 x 10 9/L 2. Platelet count = 100 x 10 9/L 3. Hemoglobin = 9 g/dL (transfusions are allowed) - Renal Function as follows: 1. Creatinine = 1.5 x upper limit of normal (ULN), or calculated glomerular filtration rate (GFR) > 40 mL/min (Cockcroft-Gault) if creatinine > 1.5x ULN - Hepatic function, as follows: 1. Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) = 2.5 x ULN or = 5x ULN if known liver metastases 2. Total bilirubin = 1.5 x ULN - Prothrombin time (PT) and activated partial thromboplastin time (aPTT) levels =1.5 x ULN. If institution does not report PT value, the international normalization ratio (INR) must be = ULN. - If subject is receiving Coumadin (warfarin), a stable international normalization ratio (INR) of 2-3 is required. - No clinical symptoms of hypothyroidism - Urine Protein to Creatinine Ratio (uPCR) < 2.0 - If uPCR = 2.0 then a 24-hour urine collection can be performed to qualify. If this is performed to qualify, the protein result must be < 2 g per 24 hours. - Female subject must either: - Be of non-childbearing potential: 1. post-menopausal (defined as at least 1 year without any menses) prior to Screening, or 2. documented surgically sterile - Or, if of childbearing potential, 1. Agree not to try to become pregnant during the study and for 6 months after the final study drug administration 2. And have a negative serum pregnancy test = 10 days of cycle 1, day 1 (C1D1) - And, if heterosexually active, agree to consistently use 2 forms of highly effective birth control* (at least one of which must be a barrier method) starting at Screening and throughout the study period and for 6 months after the final study drug administration. - Female subject must agree not to breastfeed starting at Screening and throughout the study period, and for 6 months after the final study drug administration. - Female subject must not donate ova starting at Screening and throughout the study period, and for 6 months after the final study drug administration. - Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception* consisting of 2 forms of birth control (at least one of which must be a barrier method) starting at Screening and continue throughout the study period, and for 6 months after the final study drug administration - Male subject must not donate sperm starting at Screening and throughout the study period and, for 6 months after the final study drug administration Note: *Highly effective forms of birth control include: - Consistent and correct usage of established oral contraception. - Established intrauterine device (IUD) or intrauterine system (IUS). - Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository Exclusion Criteria: - Has previously been treated with axitinib, AGS-16C3F, or AGS-16M8F - Has untreated brain metastasis. In the case of a solitary brain metastasis which has been resected, there must be evidence of a disease-free interval of at least 3 months post-surgery. For brain metastases treated with whole brain or stereotactic radiation therapy, brain imaging must be stable > 3 months. All subjects previously treated for brain metastases must be stable off corticosteroid therapy for at least 28 days prior to C1D1. - Has uncontrolled hypertension defined as blood pressure > 150/90 on medication(s) by 2 blood pressure readings taken at least 1 hour apart. - Has gastrointestinal abnormalities including: - inability to take oral medication; - requirement for intravenous alimentation; - prior surgical procedures affecting absorption including total gastric resection; - active gastrointestinal bleeding, unrelated to cancer, as evidenced by hematemesis, hematochezia or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy; - malabsorption syndromes such as celiac disease, cystic fibrosis, inflammatory bowel disease, systemic sclerosis, and carcinoid syndrome - Has ocular conditions such as: - Active infection or corneal ulcer - Monocularity - Visual acuity of 20/70 or worse in both eyes - History of corneal transplantation - Contact lens dependent (if using contact lens, must be able to switch to glasses during the entire study duration) - Uncontrolled glaucoma (topical medications allowed) - Uncontrolled or active ocular problems (e.g., retinopathy, macular edema, active uveitis, wet macular degeneration) requiring surgery, laser treatment, or intravitreal injections - Papilledema or other active optic nerve disorder - Has used any investigational drug (including marketed drugs not approved for this indication) = 14 days of C1D1. No time limit applies to the use of marketed drugs approved for this indication provided that the subject has progressed on the treatment and all toxicities attributable to the drug have resolved, returned to baseline or stabilized. - Has known sensitivity to any of the ingredients of: - investigational product AGS-16C3F and/or, - Inlyta® (axitinib) and/or, - 1% prednisolone acetate ophthalmic suspension and any other corticosteroids. - Is currently using (i.e., within 14-days prior to first dose) drugs that are known strong CYP3A4/5 inhibitors / inducers. - Thromboembolic event (e.g., deep vein thrombosis [DVT] and pulmonary embolism [PE]) = 4 weeks of C1D1. - Subjects who had a thromboembolic event = 4 weeks of C1D1 must be receiving adequate anticoagulation treatment for at least 2 weeks before C1D1 and must continue as clinically indicated post first dose - Has history bleeding disorders (e.g., pulmonary hemorrhage, significant hemoptysis, menometrorrhagia not responding to hormonal treatment) = 2 months before C1D1 - Has active angina or Class III or IV Congestive Heart Failure (New York Heart Association CHF Functional Classification System) or clinically significant cardiac disease within 6 months of randomization, including myocardial infarction, unstable angina, Grade 2 or greater peripheral vascular disease, congestive heart failure, or arrhythmias not controlled by medication. - Had major surgery = 4 weeks of C1D1 - Is pregnant (confirmed by positive serum pregnancy test) or lactating - Has active infection requiring treatment with systemic (intravenous or oral) anti-infectives (antibiotic, antifungal, or antiviral agent) = 10 days of C1D1 - Is unwilling or unable to comply with study requirements - Has any medical or psychiatric disorder that compromises the ability of the subject to give written informed consent, and/or comply with the study procedures.

Study Design


Intervention

Drug:
AGS-16C3F
Intravenous (IV) infusion
Axitinib
Oral

Locations

Country Name City State
Canada Site CA02006 Calgary Alberta
Canada Site CA02004 Edmonton Alberta
Canada Site CA02002 Hamilton Ontario
Canada Site CA02005 Kelowna British Columbia
Canada Site CA02008 London Ontario
Canada Site CA02001 Vancouver British Columbia
United States Site US01004 Ann Arbor Michigan
United States Site US01010 Atlanta Georgia
United States Site US01023 Baltimore Maryland
United States Site US01002 Boston Massachusetts
United States Site US01006 Buffalo New York
United States Site US01011 Charleston South Carolina
United States Site US01013 Detroit Michigan
United States Site US01022 Durham North Carolina
United States Site US01003 Houston Texas
United States Site US01008 La Jolla California
United States Site US01007 Los Angeles California
United States Site US01020 Los Angeles California
United States Site US01009 Milwaukee Wisconsin
United States Site US01012 Omaha Nebraska
United States Site US01019 Palo Alto California
United States Site US01021 Pittsburgh Pennsylvania
United States Site US01017 Portland Oregon
United States Site US01001 Seattle Washington
United States Site US01014 Temple Texas
United States Site US01026 Tucson Arizona

Sponsors (1)

Lead Sponsor Collaborator
Astellas Pharma Global Development, Inc.

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Investigator Radiologic Review PFS was defined as the time from the date of randomization to the earliest of documented disease progression as defined by RECIST v.1.1 or death from any cause. PFS was analysed using Kaplan-Meier estimates. Progressive disease (PD) was defined as at least a 20% increase in the sum of diameters (longest for non-nodal lesions, short axis for nodal lesions) of the target lesions taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). The appearance of 1 or more new lesions is also considered progression. Participants were censored if there were 2 or more than 2 consecutive missing assesments immediately prior to death or progression; or no death and no postebaseline assesments; or if ininitiated non protocol anticancer treatment prior to death or prior to documentation of disease progression; or alive and not progressed. From date of randomization to the earliest of either documented disease progression or death from any cause (up to 53 months)
Secondary PFS Per RECIST v1.1 as Assessed by Blinded Central Radiology Assessment PFS was defined as the time from the date of randomization to the earliest of documented disease progression as defined by RECIST v.1.1 or death from any cause. PFS was analysed using Kaplan-Meier estimates. PD was defined as at least a 20% increase in the sum of diameters (longest for non-nodal lesions, short axis for nodal lesions) of the target lesions taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. The appearance of 1 or more new lesions is also considered progression. Participants were censored if there were 2 or more than 2 consecutive missing assessments immediately prior to death or progression; or no death and no postebaseline assessments; or if initiated non protocol anticancer treatment prior to death or prior to documentation of disease progression; or alive and not progressed. From date of randomization to the earliest of either documented disease progression or death from any cause (up to 40 months)
Secondary Objective Response Rate (ORR) Based on the Investigator's Radiographic Assessment ORR was defined as the percentage of participants who had a best overall response of complete response (CR) or partial response (PR). CR was defined as disappearance of all target and nontarget lesions. Any pathological lymph nodes (whether target or nontarget) with reduction in short axis to <10mm from baseline measurement. PR was defined as at least a 30% decrease in the sum of diameters (longest for nonnodal lesions, short axis for nodal lesions) of target lesions taking as reference to the baseline sum of diameters. From date of randomization until data cutoff date of 21 August 2019 (up to 40 months)
Secondary Duration of Response (DOR) Based on the Investigator's Radiographic Assessment DOR was defined as the time from the date of the first response of CR or PR (whichever was first recorded) to the first date of documented PD or death due to any cause. DOR was analysed using Kaplan-Meier estimates. CR and PR were defined in outcome measure 3 and PD was defined in outcome measures 1 and 2. Participants were censored if there were 2 or more than 2 consecutive missing assesments immediately prior to death or progression; or no death and no postebaseline assesments; or if ininitiated non protocol anticancer treatment prior to death or prior to documentation of disease progression; or alive and not progressed. From date of first objective response until data cutoff date of 21 August 2019 (up to 40 months)
Secondary Overall Survival (OS) OS was defined as the time from the date of randomization until the date of death from any cause. OS was analysed using Kaplan-Meier estimates. Participants were censored if there was no death and no postbaseline contact or no death and at least one postbaseline follow-up. Date of randomization until the date of death from any cause (up to 53 months)
Secondary Disease Control Rate (DCR) Based on the Investigator's Radiographic Assessment DCR was defined as the percentage of patients who had a best overall response of CR, PR or at least 6 months with stable disease (SD). CR was defined as disappearance of all target and nontarget lesions. Any pathological lymph nodes (whether target or nontarget) with reduction in short axis to <10mm from baseline measurement. PR was defined as at least a 30% decrease in the sum of diameters (longest for nonnodal lesions, short axis for nodal lesions) of target lesions taking as reference to the baseline sum of diameters. SD was defined as neither sufficient decrease to qualify for PR nor sufficient increase to qualify for progressive disease taking as reference the smallest sum of diameters while on study drug. Date of randomization until data cutoff date of 21 August 2019 (up to 40 months)
Secondary Number of Participants With Adverse Events AE was defined as any untoward medical occurrence in a participant administered a study drug or has undergone study procedures and which did not necessarily have a causal relationship with this treatment. An abnormality identified during a medical test (e.g., laboratory parameter, vital sign, ECG data, and physical exam) was defined as an AE only if the abnormality induces clinical signs or symptoms or requires active intervention or requires interruption or discontinuation of study medication or the abnormality or investigational value is clinically significant in the opinion of the investigator. AE was considered "serious" if it results in death or is life threatening results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions or results in congenital anomaly, or birth defect requires inpatient hospitalization or leads to prolongation of hospitalization or other medically important events. From first dose up to 53 months
Secondary Maximum Observed Serum Concentration (Cmax) of Antibody Drug Conjugate (ADC) Cmax of ADC was reported. Predose, end of infusion, 4, 24, 72, 336 hours postdose of cycle 1 and cycle 4 (each cycle is 21 days)
Secondary Mean Predose Serum Concentration (Ctrough) of ADC Ctrough of ADC was reported. Predose on cycle 2, 3, 4, 6, 14, and 18 (each cycle is 21 days)
Secondary Time to Maximum Observed Serum Concentration (Tmax) of ADC Tmax of ADC was reported. Predose, end of infusion, 4, 24, 72, 336 hours postdose of cycle 1 and cycle 4 (each cycle is 21 days)
Secondary Area Under the Concentration Versus Time Curve From Time Zero to 21days (AUC0 to 21) of ADC AUC (0 to 21) of ADC was reported. Predose, end of infusion, 4, 24, 72, 336 hours postdose of cycle 1 and cycle 4 (each cycle is 21 days)
Secondary Terminal Elimination Half-life (t1/2) of ADC t1/2 of ADC was reported. Predose, end of infusion, 4, 24, 72, 336 hours postdose of cycle 1 and cycle 4 (each cycle is 21 days)
Secondary Maximum Serum Concentration (Cmax) of Total Antibody (TAb) Cmax of TAb was reported. Predose, end of infusion, 4, 24, 72, 336 hours postdose of cycle 1 and cycle 4 (each cycle is 21 days)
Secondary Mean Predose Serum Concnetration (Ctrough) of TAb Ctrough of TAb was reported. Predose on cycle 2, 3, 4, 6, 14, and 18 (each cycle is 21 days)
Secondary Time to Maximum Observed Serum Concentration (Tmax) of Tab Tmax of TAb was reported. Predose, end of infusion, 4, 24, 72, 336 hours postdose of cycle 1 and cycle 4 (each cycle is 21 days)
Secondary Area Under the Concentration Versus Time Curve From Time Zero to 21days (AUC0 to 21) of TAb AUC (0 to 21) of TAb was reporetd. Predose, end of infusion, 4, 24, 72, 336 hours postdose of cycle 1 and cycle 4 (each cycle is 21 days)
Secondary Terminal Elimination Half-life (t1/2) of Tab t1/2 of TAb was reported. Predose, end of infusion, 4, 24, 72, 336 hours postdose of cycle 1 and cycle 4 (each cycle is 21 days)
Secondary Maximum Serum Concentration (Cmax) of Cysteine Adduct of Maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF) Cmax of Cys-mcMMAF was reported. Predose, end of infusion, 4, 24, 72, 336 hours postdose of cycle 1 and cycle 4 (each cycle is 21 days)
Secondary Mean Predose Serum Concnetration (Ctrough) of Cys-mcMMAF Ctrough of Cys-mcMMAF was reported. Predose on cycle 2, 3, 4, 6, 14, and 18 (each cycle is 21 days)
Secondary Time to Maximum Observed Serum Concentration (Tmax) of Cys-mcMMAF Tmax of Cys-mcMMAF was reported. Predose, end of infusion, 4, 24, 72, 336 hours postdose of cycle 1 and cycle 4 (each cycle is 21 days)
Secondary Area Under the Concentration Versus Time Curve From Time Zero to 21days (AUC0 to 21) of Cys-mcMMAF AUC (0 to 21) of Cys-mcMMAF was reporetd. Predose, end of infusion, 4, 24, 72, 336 hours postdose of cycle 1 and cycle 4 (each cycle is 21 days)
Secondary Terminal Elimination Half-life (t1/2) of Cys-mcMMAF t1/2 of Cys-mcMMAF was reported Predose, end of infusion, 4, 24, 72, 336 hours postdose of cycle 1 and cycle 4 (each cycle is 21 days)
See also
  Status Clinical Trial Phase
Completed NCT00930033 - Clinical Trial to Assess the Importance of Nephrectomy Phase 3
Recruiting NCT05863351 - Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study Phase 3
Not yet recruiting NCT06284564 - A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) Phase 2
Completed NCT00414765 - Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma Phase 4
Active, not recruiting NCT03149822 - Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma Phase 1/Phase 2
Recruiting NCT03647878 - Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
Completed NCT01517243 - Phase II Study of Alternating Sunitinib and Temsirolimus Phase 2
Withdrawn NCT03927248 - PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer Phase 1/Phase 2
Terminated NCT02122003 - Second Line Sorafenib After Pazopanib in Patients With RCC Phase 2
Completed NCT01182142 - Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients Phase 2
Completed NCT00630409 - Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma Phase 2
Recruiting NCT04140526 - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Phase 1/Phase 2
Completed NCT04076787 - Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
Active, not recruiting NCT04467021 - Cancer and Blood Pressure Management, CARISMA Study N/A
Recruiting NCT05119335 - A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma Phase 1/Phase 2
Completed NCT02282579 - Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy
Completed NCT01731158 - Sequential Therapy in Metastatic Renal Cell Carinoma Phase 2
Terminated NCT02071641 - Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma Phase 2
Terminated NCT01342627 - Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma Phase 2
Active, not recruiting NCT01274273 - Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer Phase 2